News By Tag
* Drug Development
* Mathematical Modeling
* Pharmaceutical Industry
* Physiological Modeling
* Antibody Therapeutics
* More Tags...
News By Location
Dr. Birgit Schoeberl to Present in Rosa’s "Impact" World-Wide Webinar Series
Dr. Schoeberl will present “Using Mathematical Models To Set Design Criteria For Antibody-Based Therapies” April 17, 2012.
According to Dr. Schoeberl, “Monoclonal antibodies are valuable as anticancer therapeutics because of their ability to selectively bind tumor-associated target proteins like receptor tyrosine kinases. However, most tumors are dependent on more than one pathway, which implies rational antibody combinations or bispecific antibodies. In our presentation, we will illustrate the use of kinetic computational models that capture protein–protein interactions to explore antibody combinations vs. bispecific antibodies, and different formats of bispecific antibodies, to set antibody design specifications such as affinity and valence, and to predict potency.”
Register for this free webinar at www.rosaandco.com/
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
# # #
Rosa creates robust mathematical models that simulate drug effects and trial outcomes. Modeling and Simulation complement traditional experimental methods, enabling unique insights that streamline drug development and regulatory interactions.